Atlas
Market PulseSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › CAPLIPOINT

CAPLIPOINT

Caplin Point Laboratories Limited
Small-capPharma ↗

What the six lenses say about CAPLIPOINT — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹2621.4
2026-07-10
VWAP · 1Y anchor
₹2040
+28.5% from VWAP
P/E · TTM
31.1×
TTM EPS ₹84.4
52-week range
100%
position low→high
RSI(14)
67
momentum

Own sector index

Pharma ↗
Overweight

1M

+6.2%

3M

+15.8%

1Y

+16.2%

Breadth >EMA21

72%

How CAPLIPOINT’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
5.5
avg conviction decile
Leadership
0/2
active lenses · Tech & Flow
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Small-cap cohortDRaw
TechnicalD10100›

The actual numbers

Price vs VWAP (1y)+28.5%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+31.3%
Price vs 50-EMA+16.2%
RSI(14)67
RS vs Nifty 500 · 3M+50.2%
RS vs sector · 3M+37.7%
52-week range100%
Volume vs 30d avg0.65×
Volume vs 60d avg0.68×
ATR(14) · volatility102.7
Bollinger width · vol contraction0.141
FundamentalD972›

The actual numbers

Return on equity (ROE)20.6%
Return on capital (ROCE)24.6%
Operating margin36.7%
Net margin29.7%
Revenue growth · YoY+12.9%
EPS growth · YoY+19.5%
Debt / equity0.00×

Full 8-quarter history in the financials table below.

ValuationD421›

The actual numbers

P/E (TTM)31.1×
TTM EPS₹84.4
52-week range100%
CatalystD227›

The actual numbers

Earnings & momentum29
Capital actions20
Governance35

Every filing in the corporate-announcements panel below.

FlowD125›

The actual numbers

Promoter holding70.6%
Delivery · 30d avg39.6%
Up/down-day asymmetry-9.2pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Small-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D10 + D1 ) ÷ 2 = 5.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
93
Conviction score 93/100 · avg-decile strength 5.5/10
Conviction score93/100›
TechnicalD10›
FundamentalD9›
ValuationD4›
CatalystD2›
FlowD1›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-07-10.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+3.3pp
+4.2pp
+10.3pp
+53.8pp
+51.2pp
+33.8pp
Nifty 500
Broad-market baseline
+2.9pp
+4.1pp
+9.7pp
+50.2pp
+46.2pp
+30.0pp
Sector
Own-sector index
—
—
+7.3pp
+37.7pp
+31.8pp
+12.1pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

CAPLIPOINT daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
2621.40+93.00

Relative strength

RS vs baseline · rebased to 100

CAPLIPOINT ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
169.98+4.79

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)459483493502510534543600
↳ change QoQ—+5.3%+2.0%+1.8%+1.6%+4.7%+1.7%+10.5%
EBITDA (₹cr)170186194168178189190204
EBITDA margin37.1%38.4%39.3%33.5%34.9%35.4%35.0%34.0%
PAT (₹cr)125131140145151160166173
↳ change QoQ—+4.7%+7.1%+3.5%+4.1%+6.0%+3.8%+4.2%
Net margin27.2%27.1%28.4%28.9%29.6%30.0%30.6%28.8%
EPS (₹)16.3217.2218.2818.7620.1020.3221.5622.38
D/E0.000.000.00—————
YoY growth · Mar '26Revenue +19.5% YoYPAT +19.3% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 16 Jun '26
    MEDIUMgovernance
    Disclosure under SEBI Takeover Regulations
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 21 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 14 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 14 May '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 14 May '26
    MEDIUMcapital
    Dividend
    ›

    A dividend declaration — a cash return to shareholders.

    View original filing on NSE ↗
  • 14 May '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 7 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 May '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 13 Mar '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 3 Mar '26
    MEDIUMgovernance
    Cessation
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 28 Feb '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 24 Feb '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 11 Feb '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 Feb '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds CAPLIPOINT

Mutual funds holding CAPLIPOINT (5)

FundWeightAUM ₹crGrade
UTI Large & Mid Cap Reg Gr1.29%6,218
UTI Small Cap Reg Gr1.88%5,213
UTI Multi Cap Reg Gr1.35%2,042
UTI Healthcare Reg Gr4.02%1,308
Quantum Small Cap Reg Gr1.79%225

ETFs holding CAPLIPOINT (0)

No tracked ETF holds CAPLIPOINT ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma